EmCyte vs. Cervos Medical: Centrifuge Patent Dispute Dismissed With Prejudice
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | EmCyte Corporation v. Cervos Medical, LLC |
| Case Number | 1:22-cv-01564 (D. Del.) |
| Court | District of Delaware |
| Duration | Dec 2022 – Apr 2024 487 days |
| Outcome | Defendant Win — Dismissed With Prejudice |
| Patents at Issue | |
| Accused Products | Centrifuge tube assemblies for separating, concentrating, and aspirating biological fluid constituents |
Case Overview
The Parties
⚖️ Plaintiff
Florida-based medical device company specializing in point-of-care cellular therapy systems, particularly PRP and bone marrow concentrate processing.
🛡️ Defendant
Medical device company operating in an overlapping product space, offering centrifuge-based biological fluid processing systems.
The Patents at Issue
This dispute centered on two U.S. patents covering centrifuge tube assembly technology crucial for separating, concentrating, and aspirating biological fluid constituents in regenerative medicine. These patents aim to protect proprietary processing architecture in the competitive PRP device market.
- • U.S. Patent No. 10,537,888 B2 — Centrifuge tube assembly technology
- • U.S. Patent No. 10,300,481 B2 — Centrifuge tube assembly systems
Developing a centrifuge-based product?
Assess if your medical device technology might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The court entered a judgment of dismissal with prejudice following EmCyte’s stipulation. No damages were awarded, and no injunctive relief was granted. This dismissal is final, barring EmCyte from reasserting the same patent infringement claims against Cervos Medical for the same accused products.
Verdict Cause Analysis
The voluntary dismissal with prejudice by the plaintiff suggests one of several possible strategic resolutions:
- Negotiated Settlement: The most common driver, where parties reach a private agreement (licensing deal, cross-license, or business resolution).
- Plaintiff’s Strategic Reassessment: After discovery or claim construction, EmCyte may have re-evaluated litigation risks and opted to exit.
- Commercial Resolution: A business arrangement, such as a distribution agreement or market delineation, could have resolved the dispute.
Without public disclosure of settlement terms, the precise catalyst remains undisclosed. However, the with prejudice designation confirms EmCyte made a deliberate, final decision — this was not an administrative closure.
Legal Significance
While this dismissal does not create new binding precedent on centrifuge tube assembly technology, it offers instructive signals:
- Delaware’s efficiency pressures encourage resolution before costly trial phases.
- The assertion of two related patents (US10537888B2 and US10300481B2) suggests EmCyte pursued a layered IP strategy.
- Cervos Medical’s retention of sophisticated Delaware patent defense counsel likely led to credible validity and non-infringement challenges.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in medical device technology. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this technology space
- See which companies are most active in centrifuge device patents
- Understand claim construction patterns for medical devices
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device or technology.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Centrifuge tube assembly designs for biological fluids
Active IP Enforcement
In regenerative medicine device sector
Strategic Design-Arounds
Possible with early analysis
✅ Key Takeaways
Dismissal with prejudice bars reassertion — plaintiffs must carefully evaluate exit timing and terms.
Search related case law →Delaware remains a key venue for medical device patent disputes requiring sophisticated claim construction.
Explore Delaware patent dockets →Frequently Asked Questions
Two U.S. patents were asserted: U.S. Patent No. 10,537,888 B2 and U.S. Patent No. 10,300,481 B2, both covering centrifuge tube assembly systems for separating, concentrating, and aspirating biological fluid constituents.
EmCyte Corporation filed a voluntary stipulation of dismissal (ECF No. 66) on April 1, 2024. While specific reasons were not disclosed publicly, dismissals with prejudice typically reflect negotiated settlements or strategic plaintiff decisions following litigation risk reassessment.
It reinforces EmCyte’s active enforcement posture in the PRP processing device space. Companies developing similar centrifuge assemblies should conduct freedom-to-operate analyses against EmCyte’s patent portfolio, which remains enforceable against third parties.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- U.S. District Court for the District of Delaware, Case No. 1:22-cv-01564
- USPTO Patent Center — U.S. Patent No. 10,537,888 B2
- USPTO Patent Center — U.S. Patent No. 10,300,481 B2
- PatSnap — IP Intelligence Solutions for Law Firms
- PatSnap — IP Intelligence Solutions for R&D Teams
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.